Current status of generic drugs of inavolisib and solutions to alleviate high drug prices

Inavolisib (Inavolisib) is an oral targeted drug for specific types of tumors, mainly targeting cancer patients with PI3Kα mutations. As a newly launched drug, the availability of inaliset in China is gradually increasing, but it has not yet been included in medical insurance, resulting in a high financial burden for patients. Common domestic specifications include 3mg7tablets4boards and 9mg7tablets4boards. The price per box is about 30,000 yuan, which is a considerable expense for patients undergoing long-term treatment.

In overseas markets, the original drug of Inalise is more expensive, and may cost more than 200,000 yuan per box. Affected by exchange rates and import policies, the actual cost may fluctuate. This puts some patients and families who need long-term medication under tremendous financial pressure. Since no generic version of this drug has yet been launched, patients, whether at home or overseas, can only rely on the original drug, which further limits the affordability of the drug.

Currently, there are no generics of inaliside available in China, which means that patients cannot reduce treatment costs through low-cost generics. In this case, some patients can obtain relatively economical and feasible treatment options by participating in clinical trials, pharmaceutical company patient assistance programs, or overseas drug purchase projects. For example, some international pharmaceutical companies have launched limited patient assistance programs for new drugs, providing free or discounted drugs to eligible patients to alleviate the financial pressure caused by high drug prices.

In the long term, promoting the development and approval of generic drugs is a key way to reduce the cost of inalise treatment. Once generics become available, prices are expected to drop significantly, providing accessibility to more patients. At the same time, when choosing drug purchase channels, patients should ensure that the sources of drugs are regular and reliable, and use drugs rationally under the guidance of professional doctors to ensure efficacy and safety. At the current stage, through various methods such as clinical trials, assistance plans, and medical insurance negotiations, patients' financial pressure can be alleviated to a certain extent and the sustainability of treatment can be improved.

Reference link:https://www.drugs.com